Firms will not pursue a previously announced plan to collaborate on joint development and marketing of immunotoxins for use in treatment of bone marrow transplant rejection. Xoma said it intends to expand its bone marrow program to additional applications and Cooper has decided to focus on respiratory care. (NEW LINE)
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.